Abstract
Identification and characterisation of tumour associated antigens is a pre-requisite for an effective and targeted immunotherapy. Tumour antigens are used as markers to improve diagnosis and to predict the outcome of a cancer. This review emphasises on a few important cellular target molecules such as indoleamine 2,3-dioxygenase (IDO), interleukin- 15 (IL15), mucin 1 (MUC1) and Major histocompatibility complex class I related chain A and B (MICA/B) which are involved in the downstream pathways of cancer progression. Unique aberrant and over-expression of these molecular targets modulates the physiological and immunological micro-environments in the host tissue. IDO, IL15 and MICA/B provoke NK cell and dendritic cell mediated anti-tumour responses due to their strong binding affinity to activator receptors on the immune cells. The application of these random markers derived from immunological mechanisms may help to improve and delineate some of the predictive indicators obtained with random serum profiles.
Keywords: IDO - Indoleamine 2,3-dioxygenase, MIC - Major histocompatibility complex (MHC) class I related chain A, ADCC, –, Antibody dependent cellular cytotoxicity, AIDC, Activation induced cell death, MUC1, Mucin 1, TAA, Tumour associated antigen
Current Cancer Therapy Reviews
Title: NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy
Volume: 4 Issue: 2
Author(s): Renu Datta, Catherine L. Riley, Italo A. Dodi and Robert C. Rees
Affiliation:
Keywords: IDO - Indoleamine 2,3-dioxygenase, MIC - Major histocompatibility complex (MHC) class I related chain A, ADCC, –, Antibody dependent cellular cytotoxicity, AIDC, Activation induced cell death, MUC1, Mucin 1, TAA, Tumour associated antigen
Abstract: Identification and characterisation of tumour associated antigens is a pre-requisite for an effective and targeted immunotherapy. Tumour antigens are used as markers to improve diagnosis and to predict the outcome of a cancer. This review emphasises on a few important cellular target molecules such as indoleamine 2,3-dioxygenase (IDO), interleukin- 15 (IL15), mucin 1 (MUC1) and Major histocompatibility complex class I related chain A and B (MICA/B) which are involved in the downstream pathways of cancer progression. Unique aberrant and over-expression of these molecular targets modulates the physiological and immunological micro-environments in the host tissue. IDO, IL15 and MICA/B provoke NK cell and dendritic cell mediated anti-tumour responses due to their strong binding affinity to activator receptors on the immune cells. The application of these random markers derived from immunological mechanisms may help to improve and delineate some of the predictive indicators obtained with random serum profiles.
Export Options
About this article
Cite this article as:
Datta Renu, Riley L. Catherine, Dodi A. Italo and Rees C. Robert, NK Cell, Monocyte and Non T Cell Biomarkers as Prognostic Indicators in Cancer Immunotherapy, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310133
DOI https://dx.doi.org/10.2174/157339408784310133 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
Current Pharmaceutical Design Cdc25A Protein Phosphatase: A Therapeutic Target for Liver Cancer Therapies
Anti-Cancer Agents in Medicinal Chemistry Modulators of Vascular Sex Hormone Receptors and their Effects in Estrogen-Deficiency States Associated with Menopause
Recent Patents on Cardiovascular Drug Discovery Estrogen, Neuroprotection and Neurogenesis after Ischemic Stroke
Current Drug Targets Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry A Novel Treatment Strategy for Sepsis and Septic Shock Based on the Interactions between Prostanoids, Nitric Oxide, and 20-Hydroxyeicosatetraenoic Acid
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Recent Patents Related to Phosphorylation Signaling Pathway on Cancer
Recent Patents on DNA & Gene Sequences Angiogenesis and Microvasculature in the Female Reproductive Organs: Physiological and Pathological Implications
Current Pharmaceutical Design Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Therapeutic Perspectives of Inhibitors of Endocannabinoid Degradation
Current Drug Targets - CNS & Neurological Disorders Antifolate Inhibitors of Thymidylate Synthase as Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Flavonoids as Prospective Aromatase Inhibitors in Breast Cancer Prevention/ Therapy
Current Molecular Pharmacology The Immunomodulation and Anti-Inflammatory Effects of Garlic Organosulfur Compounds in Cancer Chemoprevention
Anti-Cancer Agents in Medicinal Chemistry Anti-cancer Research on Arnebiae radix-derived Naphthoquinone in Recent Five Years
Recent Patents on Anti-Cancer Drug Discovery Advances in Regulating Tumorigenicity and Metastasis of Cancer Through TrkB Signaling
Current Cancer Drug Targets Recent Techniques Used in Reproductive Medicine: Outcomes for Gametes Manipulation
Current Women`s Health Reviews Multiple Biological Activities of Lactic Acid in Cancer: Influences on Tumor Growth,Angiogenesis and Metastasis
Current Pharmaceutical Design DNA Mismatch Repair Deficiency, Resistance to Cancer Chemotherapy and the Development of Hypersensitive Agents
Current Topics in Medicinal Chemistry Human UDP-Glucuronosyltransferase 2B7
Current Drug Metabolism